Derek L. Stirewalt

Oncology
825 Eastlake Ave E
Seattle, WA 98109

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications

Significance of CD34+ Cell Dose on Outcomes of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation in AML: An Analysis Stratified by MRD Status.

Significance of CD34+ Cell Dose on Outcomes of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation in AML: An Analysis Stratified by MRD Status.

Journal: Transplantation and cellular therapy
Published: May 22, 2026

Prognostic impact of age and MDS-associated mutations in NPM1 -mutated AML.

Prognostic impact of age and MDS-associated mutations in NPM1 -mutated AML.

Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025

Prognostic impact of age and MDS-associated mutations in NPM1-mutated AML.

Prognostic impact of age and MDS-associated mutations in NPM1-mutated AML.

Journal: Blood neoplasia
Published: November 21, 2025

MDS-associated SF3B1 mutations promote aberrant fate choice of hematopoietic stem cell via mis-splicing of mediator kinase module component CDK8.

MDS-associated SF3B1 mutations promote aberrant fate choice of hematopoietic stem cell via mis-splicing of mediator kinase module component CDK8.

Journal: bioRxiv : the preprint server for biology
Published: September 02, 2025

Evaluation of acute myeloid leukemia using genomic proximity mapping-based next generation cytogenomics.

Evaluation of acute myeloid leukemia using genomic proximity mapping-based next generation cytogenomics.

Journal: Haematologica
Published: June 17, 2025

CD34+ Cell Dose, Measurable Residual Disease, and Outcome After Myeloablative HLA-Matched Peripheral Blood Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia.

CD34+ Cell Dose, Measurable Residual Disease, and Outcome After Myeloablative HLA-Matched Peripheral Blood Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia.

Journal: Cancers
Published: June 06, 2025

Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration.

Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 02, 2024

Pretransplant Chromosome Genomic Array Testing Improves Prognostication for Myelofibrosis Patients Undergoing Transplantation.

Pretransplant Chromosome Genomic Array Testing Improves Prognostication for Myelofibrosis Patients Undergoing Transplantation.

Journal: Transplantation and cellular therapy
Published: October 22, 2024

Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG report.

Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG report.

Journal: EJHaem
Published: September 09, 2024

Evaluation of Acute Myeloid Leukemia Genomes using Genomic Proximity Mapping.

Evaluation of Acute Myeloid Leukemia Genomes using Genomic Proximity Mapping.

Journal: medRxiv : the preprint server for health sciences
Published: June 10, 2024

SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms.

SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms.

Journal: Cancer immunology research
Published: January 24, 2024

Discovery of U2AF1 neoantigens in myeloid neoplasms.

Discovery of U2AF1 neoantigens in myeloid neoplasms.

Journal: Journal for immunotherapy of cancer
Published: November 19, 2023
Showing 1-12 of 45

Last Updated: 09/26/2026